Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

Nasdaq Stockholm

Price

Change

Latest investor news

May 15, 2026

Oncopeptalks: Q1 report

Investor

May 13, 2026

Redeye interviews Oncopeptides CEO Sofia Heigis

Investor

May 8, 2026

Launching: Oncopeptalks as a podcast

Investor

March 23, 2026

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Investor

March 20, 2026

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Investor

March 11, 2026

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

Investor

March 5, 2026

Biostock: presentation and interview with Sofia Heigis

Investor

February 20, 2026

Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue

Investor

May 13, 2026

COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Science

May 13, 2026

Oncopeptides publishes Q1 report 2026

May 11, 2026

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

May 6, 2026

Invitation to presentation of the Q1 report 2026

No upcoming events

Investor Relations Contact

David Augustsson, MSc

Director of IR and Communications

ir@oncopeptides.com

+46 762 29 38 68

Investors

Latest investor news

Investor Relations Contact

More investor information

The share

General Meeting

Financial Reports

Financial Calendar